Business Wire

CA-QUANERGY-SYSTEMS

26.9.2018 16:11:02 CEST | Business Wire | Press release

Share
Quanergy Announces Availability of Power Over Ethernet for M8 LiDAR Sensor

Quanergy Systems, Inc., a global leader in the design and development of solid state LiDAR sensors and smart sensing solutions, today announced the availability of its M8 LiDAR sensor with Power over Ethernet (PoE+). This new connector interface, designed specifically for the security market, allows the sensor to be easily installed and integrated with new or existing security systems, without costly custom wiring to power the LiDAR sensor.

Surveillance systems leverage PoE to transmit power and data across the sensor and system. The IEEE 802.3at (PoE+) specification provides more power to PoE-powered devices and allows for a broader range of devices to be easily integrated into a network via standard Ethernet cable. The release of the M8 with PoE+ allows for a simpler, more flexible installation of LiDAR-based security systems. Its plug-and-play usability permits customers to make use of their existing security infrastructure when upgrading to a LiDAR-based security solution, leading to significant savings in implementation cost and time.

The M8 sensor’s long range and 360 degree field of view enables systems to detect and track potential intruders before they physically breach a perimeter. The M8 PoE+ provides a signifcantly smaller overall footprint than other PoE+ sensors and radars. Unlike traditional security camera technology, the M8 operates successfully in challenging weather environments as well as in the dark. Paired with Quanergy’s proprietary LiDAR perception software, QORTEX for Security™, the M8 can be used as a standalone solution, or as an integrated component of a larger security system.

“We built the M8 with Power over Ethernet to enable our security customers to implement a LiDAR-based security system as easily as they would a camera-based surveillance system,” said Dr. Louay Eldada, CEO of Quanergy. “Our LiDAR sensors lead the industry in price, performance, and reliability. With PoE+, our customers can easily harness the power of LiDAR to ensure the highest level of security and awareness around vulnerable perimeters, protecting critical infrastructure such as airports, national borders, subways, power plants, oil fields and prisons.”

In addition to offering its technology as a standalone security solution, Quanergy deploys its technology in partnership with public safety and security technology firms (system integrators or SI) such as Vision Logic, many of whom are already using Power over Ethernet to connect other surveillance tools, such as IP cameras. This new availability allows SIs to flexibly incorporate Quanergy’s LiDAR technology into existing security systems, reducing installation time and costs.

“Integrating LiDAR technology into our video surveillance and facial recognition systems enables us to offer an unparalleled level of security and awareness to our customers,” said John Walsh, co-founder of Vision Logic. Graham Conran, co-founder and CEO of Vision Logic added “With Power over Ethernet, we can more easily incorporate Quanergy’s industry leading LiDAR sensors into our public safety and security platforms, tailoring our solutions to each of our customers’ needs.”

The M8 with PoE+ will be on display at two leading security industry events. Quanergy will be exhibiting at GSX in Las Vegas, September 25-27, in booth #2885. At Security Essen in Germany, September 26-28, the sensor will be in both the Milestone Systems and Genetec booths in Hall 5. Genetec will be in booth #5G30 and Miletsone will be in booth #5F10. General availability of the M8 sensor with PoE+ is November 2018.

About Quanergy Systems, Inc.

Quanergy Systems, Inc. was founded in 2012 and builds on decades of experience of its team in the areas of optics, photonics, optoelectronics, artificial intelligence software and control systems. Headquartered in Sunnyvale, California, in the heart of Silicon Valley, Quanergy offers smart sensing solutions. It is the leading provider of LiDAR sensors and perception software for real-time capture and processing of 3D spatial data and object detection, identification, classification and tracking. Its sensors are disruptive in price, performance, reliability, size, weight and power. Its solutions are applicable in numerous sectors including transportation, security, industrial automation, 3D mapping, mining, agriculture, drones, robotics, smart spaces and 3D-aware smart devices for improved safety, efficiency and quality of life. For more information, visit www.quanergy.com .

Contact:

Quanergy Systems, Inc. Ann Gargiulo, +1-408-245-9500 Director of Marketing Communications media@quanergy.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye